microdose glp 1 alcohol GLP-1 Injections mindful eating Safety Information forProactive HealthMicrodose GLP-1Rx

Accordingly, and in line with currently ongoing trials in HFpEF (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not

In particular, incretin-based therapies and sodium-glucose co-transporter 2 (SGLT2) inhibitors have attracted increasing interest not only for their glucose-lowering effects, but also for their broader metabolic, renal, and cardiovascular benefits

However, combined use intensifies metabolic shiftsblood glucose may drop more rapidly, and gastrointestinal effects from GLP-1 (nausea, constipation) may be compounded by inositol's osmotic properties if doses are not carefully timed

Following his fellowship at Lilly, Tschp led a research team at the German Institute of Human Nutrition and then in 2003 became Professor of Endocrinology and Diabetes at the University of Cincinnati